- Home
- GXO vs GH Comparison
GXO vs GH Comparison
Compare GXO & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GXO
- GH
- Stock Information
- Founded
- GXO 2021
- GH 2011
- Country
- GXO United States
- GH United States
- Employees
- GXO N/A
- GH N/A
- Industry
- GXO Transportation Services
- GH Medical Specialities
- Sector
- GXO Consumer Discretionary
- GH Health Care
- Exchange
- GXO Nasdaq
- GH Nasdaq
- Market Cap
- GXO 4.8B
- GH 4.9B
- IPO Year
- GXO N/A
- GH 2018
- Fundamental
- Price
- GXO $51.19
- GH $53.08
- Analyst Decision
- GXO Buy
- GH Strong Buy
- Analyst Count
- GXO 13
- GH 18
- Target Price
- GXO $60.62
- GH $55.67
- AVG Volume (30 Days)
- GXO 1.0M
- GH 2.8M
- Earning Date
- GXO 08-05-2025
- GH 07-30-2025
- Dividend Yield
- GXO N/A
- GH N/A
- EPS Growth
- GXO N/A
- GH N/A
- EPS
- GXO 0.53
- GH N/A
- Revenue
- GXO $12,683,000,000.00
- GH $828,849,000.00
- Revenue This Year
- GXO $10.33
- GH $23.36
- Revenue Next Year
- GXO $6.62
- GH $21.43
- P/E Ratio
- GXO $95.96
- GH N/A
- Revenue Growth
- GXO 22.39
- GH 28.74
- 52 Week Low
- GXO $30.46
- GH $20.14
- 52 Week High
- GXO $63.33
- GH $53.68
- Technical
- Relative Strength Index (RSI)
- GXO 55.25
- GH 65.69
- Support Level
- GXO $45.75
- GH $43.66
- Resistance Level
- GXO $52.28
- GH $46.25
- Average True Range (ATR)
- GXO 1.44
- GH 2.42
- MACD
- GXO -0.30
- GH 0.83
- Stochastic Oscillator
- GXO 70.36
- GH 98.18
About GXO GXO Logistics Inc.
GXO Logistics Inc is a contract logistics company. Its revenue is diversified across numerous verticals and customers, including many multinational corporations. It provides warehousing and distribution, order fulfillment, e-commerce, reverse logistics, and other supply chain services differentiated by its ability to deliver technology-enabled, customized solutions at scale. Geographically, it generates revenue from the United Kingdom, the United States, the Netherlands, France, Spain, Italy, and other countries, and derives the majority of its revenue from the United Kingdom.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.